Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab

References

• Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168:1303 - 10; http://dx.doi.org/10.1111/bjd.12230; PMID: 23374051
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10:1 - 233, i-iv; PMID: 17083854
   PubMed Web of Science ®Google Scholar
• Stern RS. Psoriasis. Lancet 1997; 350:349 - 53; http://dx.doi.org/10.1016/S0140-6736(97)05257-4; PMID: 9251649
   PubMed Web of Science ®Google Scholar
• Kim IH, West CE, Kwatra SG, Feldman SR, O’Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012; 13:365 - 74; http://dx.doi.org/10.2165/11633110-000000000-00000; PMID: 22967166
   PubMed Web of Science ®Google Scholar
• Traub M, Marshall K. Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007; 12:319 - 30; PMID: 18069901
   PubMed Web of Science ®Google Scholar
• Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. Dermatol Ther 2009; 22:431 - 40; http://dx.doi.org/10.1111/j.1529-8019.2009.01259.x; PMID: 19845720
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13:242 - 4; http://dx.doi.org/10.1038/nm0307-242; PMID: 17342112
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866 - 73; http://dx.doi.org/10.1038/nature05663; PMID: 17314973
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496 - 509; http://dx.doi.org/10.1056/NEJMra0804595; PMID: 19641206
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1 - 23, quiz 23-6; http://dx.doi.org/10.1067/mjd.2002.120568; PMID: 11756941
   PubMed Web of Science ®Google Scholar
• Hassan NJ, Barclay AN, Brown MH. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 2004; 34:930 - 40; http://dx.doi.org/10.1002/eji.200424856; PMID: 15048703
   PubMed Web of Science ®Google Scholar
• Gimferrer I, Calvo M, Mittelbrunn M, Farnós M, Sarrias MR, Enrich C, Vives J, Sánchez-Madrid F, Lozano F. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004; 173:2262 - 70; PMID: 15294938
   PubMed Web of Science ®Google Scholar
• Aruffo A, Melnick MB, Linsley PS, Seed B. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J Exp Med 1991; 174:949 - 52; http://dx.doi.org/10.1084/jem.174.4.949; PMID: 1919444
   PubMed Web of Science ®Google Scholar
• Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, Bajorath J. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997; 36:2637 - 41; http://dx.doi.org/10.1021/bi962560+; PMID: 9054570
   PubMed Web of Science ®Google Scholar
• Ibáñez A, Sarrias MR, Farnós M, Gimferrer I, Serra-Pagès C, Vives J, Lozano F. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006; 177:1152 - 9; PMID: 16818773
   PubMed Web of Science ®Google Scholar
• Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 2002; 14:585 - 97; http://dx.doi.org/10.1093/intimm/dxf025; PMID: 12039910
   PubMed Web of Science ®Google Scholar
• Le Dantec C, Alonso R, Fali T, Montero E, Devauchelle V, Saraux A, Pers JO, Renaudineau Y. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res 2013; 56:341 - 7; http://dx.doi.org/10.1007/s12026-013-8423-x; PMID: 23576060
   PubMed Web of Science ®Google Scholar
• Alonso-Ramirez R, Loisel S, Buors C, Pers JO, Montero E, Youinou P, Renaudineau Y. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis 2010; 2010:130646.
   Google Scholar
• Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Strom TB, Tilney NL. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 1983; 36:620 - 6; http://dx.doi.org/10.1097/00007890-198336060-00005; PMID: 6197792
   PubMed Web of Science ®Google Scholar
• Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, Fitzgerald KA, Daley JF, Levine H, Rosen FS, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A 1982; 79:6047 - 51; http://dx.doi.org/10.1073/pnas.79.19.6047; PMID: 6764536
   PubMed Web of Science ®Google Scholar
• Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986; 36:777 - 84; http://dx.doi.org/10.1212/WNL.36.6.777; PMID: 3486383
   PubMed Web of Science ®Google Scholar
• Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cénit MC, de las Heras V, Barcina MG, Arroyo R, et al. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. J Neuroimmunol 2010; 223:100 - 3; http://dx.doi.org/10.1016/j.jneuroim.2010.03.020; PMID: 20430450
   PubMed Web of Science ®Google Scholar
• Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, Cross AH, De Jager PL, Gourraud PA, Cree BC, et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun 2010; 11:343 - 50; http://dx.doi.org/10.1038/gene.2009.81; PMID: 19865102
   PubMed Web of Science ®Google Scholar
• Alonso R, Buors C, Le Dantec C, Hillion S, Pers JO, Saraux A, Montero E, Marianowski R, Loisel S, Devauchelle V, et al. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren’s syndrome. J Autoimmun 2010; 35:336 - 41; http://dx.doi.org/10.1016/j.jaut.2010.07.005; PMID: 20810246
   PubMed Web of Science ®Google Scholar
• Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernández A, Sosa K, Morrison SL, Pérez R. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003; 22:245 - 57; http://dx.doi.org/10.1089/153685903322328974; PMID: 14511570
   PubMedGoogle Scholar
• Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt) 2008; 27:291 - 301; http://dx.doi.org/10.1089/hyb.2008.0007; PMID: 18707547
   PubMed Web of Science ®Google Scholar
• Rodríguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernández IM, Hernández MV, Martinez JP, Hernández X, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012; 2:204 - 11; http://dx.doi.org/10.1016/j.rinim.2012.11.001; PMID: 24371585
   PubMedGoogle Scholar
• Nair P, Melarkode R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010; 162:116 - 30; http://dx.doi.org/10.1111/j.1365-2249.2010.04235.x; PMID: 20726988
   PubMed Web of Science ®Google Scholar
• Morera Y, Delgado J, González L, Montero JE, Tormo BR, Daniel C, Falcón L, Torres O. Estudio morfométrico comparativo del tratamiento con Calcipotriol y anticuerpo monoclonal ior t1 tópico en pacientes psoriáticos. Rev CENIC Cienc Biol 2005; 31:121 - 7
   Google Scholar
• Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A 2011; 79:95 - 101; http://dx.doi.org/10.1002/cyto.a.21010; PMID: 21265003
   PubMed Web of Science ®Google Scholar
• Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs 2010; 19:195 - 213; http://dx.doi.org/10.1517/13543780903418452; PMID: 20050823
   PubMed Web of Science ®Google Scholar
• Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54:Suppl 2 S67 - 80; http://dx.doi.org/10.1016/j.jaad.2005.10.057; PMID: 16488332
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Grindlay DJC, Griffiths CEM, Warren RB. What’s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. Clin Exp Dermatol 2011; 36:585 - 9, quiz 588-9; http://dx.doi.org/10.1111/j.1365-2230.2011.04108.x; PMID: 21718345
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174:164 - 73; PMID: 15611238
   PubMed Web of Science ®Google Scholar
• Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD. Identification and quantitation of interferon-γ producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998; 111:1072 - 8; http://dx.doi.org/10.1046/j.1523-1747.1998.00419.x; PMID: 9856819
   PubMed Web of Science ®Google Scholar
• Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257 - 70; http://dx.doi.org/10.1046/j.1468-3083.2003.00720.x; PMID: 12702062
   PubMed Web of Science ®Google Scholar
• Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102:145 - 9; http://dx.doi.org/10.1111/1523-1747.ep12371752; PMID: 8106745
   PubMed Web of Science ®Google Scholar
• Strange P, Cooper KD, Hansen ER, Fisher G, Larsen JK, Fox D, Krag C, Voorhees JJ, Baadsgaard O. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 1993; 101:695 - 700; http://dx.doi.org/10.1111/1523-1747.ep12371678; PMID: 8228331
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145 - 58; http://dx.doi.org/10.1016/S0002-9440(10)65109-7; PMID: 10393847
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25:574 - 80; http://dx.doi.org/10.1016/j.clindermatol.2007.08.012; PMID: 18021895
   PubMed Web of Science ®Google Scholar
• Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112:1571 - 80; http://dx.doi.org/10.1172/JCI200318986; PMID: 14617758
   PubMed Web of Science ®Google Scholar
• Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006; 107:3212 - 20; http://dx.doi.org/10.1182/blood-2005-09-3881; PMID: 16352806
   PubMed Web of Science ®Google Scholar
• Ibáñez A, Sarrias MR, Farnós M, Gimferrer I, Serra-Pagès C, Vives J, Lozano F. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006; 177:1152 - 9; PMID: 16818773
   PubMed Web of Science ®Google Scholar
• Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq M. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol 2005; 44:82 - 3; http://dx.doi.org/10.1111/j.1365-4632.2004.02082.x; PMID: 15663670
   PubMed Web of Science ®Google Scholar
• Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005:273 - 9; http://dx.doi.org/10.1155/MI.2005.273; PMID: 16258194
   PubMed Web of Science ®Google Scholar
• Almakhzangy I, Gaballa A. Serum level of IL-17, IL-22, IFN-γ in patients with psoriasis. . Dermatol Online J 2009; 15:5
   Google Scholar
• Szegedi A, Aleksza M, Gonda A, Irinyi B, Sipka S, Hunyadi J, Antal-Szalmás P. Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett 2003; 86:277 - 80; http://dx.doi.org/10.1016/S0165-2478(03)00025-7; PMID: 12706531
   PubMed Web of Science ®Google Scholar
• Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16:779 - 98; http://dx.doi.org/10.1111/j.1600-0625.2007.00629.x; PMID: 17845210
   PubMed Web of Science ®Google Scholar
• Verghese B, Bhatnagar S, Tanwar R, Bhattacharjee J. Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India. Indian J Clin Biochem 2011; 26:373 - 7; http://dx.doi.org/10.1007/s12291-011-0156-9; PMID: 23024473
   PubMedGoogle Scholar
• Banno T, Adachi M, Mukkamala L, Blumenberg M. Unique keratinocyte-specific effects of interferon-γ that protect skin from viruses, identified using transcriptional profiling. Antivir Ther 2003; 8:541 - 54; PMID: 14760888
   PubMed Web of Science ®Google Scholar
• Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-α (TNF α) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004; 279:32633 - 42; http://dx.doi.org/10.1074/jbc.M400642200; PMID: 15145954
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135:1 - 8; http://dx.doi.org/10.1111/j.1365-2249.2004.02310.x; PMID: 14678257
   PubMed Web of Science ®Google Scholar
• Sanchez AP. Immunopathogenesis of psoriasis. An Bras Dermatol 2010; 85:747 - 9; http://dx.doi.org/10.1590/S0365-05962010000500028; PMID: 21152809
   PubMed Web of Science ®Google Scholar
• Hirotsu C, Rydlewski M, Araújo MS, Tufik S, Andersen ML. Sleep loss and cytokines levels in an experimental model of psoriasis. PLoS One 2012; 7:e51183; http://dx.doi.org/10.1371/journal.pone.0051183; PMID: 23226485
   PubMedGoogle Scholar
• Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64:Suppl 2 ii30 - 6; http://dx.doi.org/10.1136/ard.2004.031120; PMID: 15708932
   PubMed Web of Science ®Google Scholar
• Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D’Agosto G, Cordiali-Fei P, Berardesca E. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005; 153:531 - 6; http://dx.doi.org/10.1111/j.1365-2133.2005.06648.x; PMID: 16120138
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res 2010; 47:185 - 206; http://dx.doi.org/10.1007/s12026-009-8150-5; PMID: 20087682
   PubMed Web of Science ®Google Scholar
• Hofmann SR, Rösen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 2012; 143:116 - 27; http://dx.doi.org/10.1016/j.clim.2012.02.005; PMID: 22459704
   PubMed Web of Science ®Google Scholar
• Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29:71 - 109; http://dx.doi.org/10.1146/annurev-immunol-031210-101312; PMID: 21166540
   PubMed Web of Science ®Google Scholar
• Glowacka E, Lewkowicz P, Rotsztejn H, Zalewska A. IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 2010; 55:254 - 60; http://dx.doi.org/10.2478/v10039-010-0037-0; PMID: 20934961
   PubMed Web of Science ®Google Scholar
• Döcke WD, Asadullah K, Belbe G, Ebeling M, Höflich C, Friedrich M, Sterry W, Volk HD. Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J Leukoc Biol 2009; 85:582 - 93; http://dx.doi.org/10.1189/jlb.0408249; PMID: 19038787
   PubMed Web of Science ®Google Scholar
• Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Krueger JG. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104:1527 - 37; http://dx.doi.org/10.1172/JCI6910; PMID: 10587516
   PubMed Web of Science ®Google Scholar
• Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powles AV, Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996; 288:421 - 5; http://dx.doi.org/10.1007/BF02505228; PMID: 8844118
   PubMed Web of Science ®Google Scholar
• Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177:4917 - 26; PMID: 16982934
   PubMed Web of Science ®Google Scholar
• Borghi A, Fogli E, Stignani M, Melchiorri L, Altieri E, Baricordi O, Rizzo R, Virgili A. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch Dermatol Res 2008; 300:551 - 9; http://dx.doi.org/10.1007/s00403-008-0886-6; PMID: 18797896
   PubMed Web of Science ®Google Scholar
• Roussaki-Schulze AV, Kouskoukis C, Petinaki E, Klimi E, Zafiriou E, Galanos A, Rallis E. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res 2005; 25:169 - 73; PMID: 16402633
   PubMedGoogle Scholar
• Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000; 19:101 - 5; http://dx.doi.org/10.1007/s002960050111; PMID: 10776688
   PubMed Web of Science ®Google Scholar
• Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62:383 - 91; PMID: 20112361
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101:783 - 94; http://dx.doi.org/10.1172/JCI1476; PMID: 9466973
   PubMed Web of Science ®Google Scholar
• Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995; 105:Suppl 89S - 94S; http://dx.doi.org/10.1038/jid.1995.18; PMID: 7616005
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6:R326 - 34; http://dx.doi.org/10.1186/ar1182; PMID: 15225368
   PubMed Web of Science ®Google Scholar
• Mahiques L, Pitarch G, Sánchez-Carazo JL, Pérez-Ferriols A, Soriano CJ, Alegre V. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]. Actas Dermosifiliogr 2007; 98:539 - 44; http://dx.doi.org/10.1016/S0001-7310(07)70129-1; PMID: 17919428
   PubMedGoogle Scholar
• Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721 - 9; PMID: 16081850
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248 - 55; http://dx.doi.org/10.1056/NEJM200107263450403; PMID: 11474662
   PubMed Web of Science ®Google Scholar
• de Groot M, Picavet DI, van Kuijk AW, Tak PP, Bos JD, de Rie MA, Teunissen MB. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology 2012; 225:298 - 303; http://dx.doi.org/10.1159/000343290; PMID: 23257348
   PubMed Web of Science ®Google Scholar
• Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, Wang Y, Pendley C, Prabhakar U, Wong J, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37:413 - 25; http://dx.doi.org/10.1111/j.1346-8138.2010.00802.x; PMID: 20536646
   PubMed Web of Science ®Google Scholar
• Jullien D. Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. Ann Dermatol Venereol 2012; 139:Suppl 2 S58 - 67; http://dx.doi.org/10.1016/S0151-9638(12)70112-6; PMID: 22541730
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40:389 - 92; http://dx.doi.org/10.1111/1346-8138.12093; PMID: 23414225
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013; 12:703 - 8; http://dx.doi.org/10.1016/j.autrev.2012.10.021; PMID: 23207283
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Wei JC, Nurmohamed MT, Jeo KJ, Chen CY, van der Horst-Bruinsma IE, van der Kleij D, Rispens T, Wolbink G, Krieckaert CLM. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Dec 10, 2013. doi: http://dx.doi.org/10.1136/annrheumdis-2013-204185.
   Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 76 week results from a randomized, double blind, placebo controlled trial (Phoenix 1). Lancet 2008; 371:1665 - 74; http://dx.doi.org/10.1016/S0140-6736(08)60725-4; PMID: 18486739
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 52 week results from a randomized, double blind, placebo controlled trial (Phoenix 2). Lancet 2008; 371:1675 - 84; http://dx.doi.org/10.1016/S0140-6736(08)60726-6; PMID: 18486740
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64:Suppl 2 ii65 - 8, discussion ii69-73; http://dx.doi.org/10.1136/ard.2004.031237; PMID: 15708941
   PubMed Web of Science ®Google Scholar
• Coro RM, Borrajero I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev Latinoam Patol 1996; 34:9 - 10
   Google Scholar
• Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995; 38:1457 - 65; http://dx.doi.org/10.1002/art.1780381012; PMID: 7575695
   PubMed Web of Science ®Google Scholar